Grand Pharmaceutical Group (HKG:0512) has completed its phase III clinical trial of GPN00833 and met its clinical endpoint, a Monday bourse filing said.
GPN00833 is an anti-inflammatory and analgesic hormone nanosuspension eye drop.
The study showed a significantly higher percentage of patients with zero anterior chamber cell counts from the eighth to the 15th day post-surgery as compared to patients in the placebo group.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。